Responses
EULAR 2014: Scientific Abstracts
Oral Presentations. Abstract session: RA - non biologic and small molecules
OP0151 A Phase 2B, 24-Week Study of VX-509 (DECERNOTINIB), an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
Compose a Response to This Article
Other responses
No responses have been published for this article.